Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models

Wei‐Pang Chung,Wei‐Lun Huang,Wei‐An Liao,Wan‐Ling Huang,You‐Yu Liu,Wu‐Chou Su

DOI: https://doi.org/10.1002/cam4.3824

IF: 4.711

2021-03-05

Cancer Medicine

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who fail to respond to anti‐HER2 treatments have poor prognoses. Most trastuzumab‐resistant breast cancer cell lines available from biobanks feature either <i>phosphoinositide‐3‐kinase</i>, <i>catalytic</i>, <i>alpha</i> (<i>PIK3CA</i>) mutation or the loss of phosphatase and tensin homolog (PTEN). However, <i>PIK3CA</i> mutations and/or PTEN loss do not account for most trastuzumab‐resistant tumors in humans. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Breast cancer cells were collected from one patient's malignant ascites. These cells were cultured and maintained to develop a stable cell line, which we named CK‐MB‐1. We used western blotting to evaluate protein expression. The <i>PIK3CA</i> status of CK‐MB‐1 cells was analyzed using Sanger sequencing and validated using next‐generation sequencing. In vivo, CK‐MB‐1 xenograft tumor models were developed in zebrafish and immunodeficient mice. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>CK‐MB‐1 cells maintained the major characteristics of the parental tumor including HER2 positivity and estrogen receptor negativity. The HER2 gene amplification of CK‐MB‐1 cells was detected by fluorescence in situ hybridization. The integrity of PTEN was confirmed by its positive protein expression and the absence of gene mutations. No common <i>PIK3CA</i> mutation was detected. Compared with the findings in two other HER2‐positive trastuzumab‐resistant cell lines, CK‐MB‐1 cells exhibited greater resistance to trastuzumab, chemotherapeutics, and small‐molecule drugs. Trastuzumab resistance in CK‐MB‐1 cells was confirmed in vivo using the NOD SCID mouse model. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>CK‐MB‐1 cells represent a stable HER2‐positive trastuzumab‐resistant breast cancer cell line. The resistance of CK‐MB‐1 cells does not originate from the PTEN or phosphoinositide 3‐kinase signaling pathway, which can provide an alternative approach for potential drugs.</p></section>

oncology

What problem does this paper attempt to address?

The main purpose of this paper is to develop a trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell line and its xenograft animal model.

Specifically, the research team isolated tumor cells from the malignant ascites of a HER2-positive breast cancer patient who had disease progression despite multiple lines of anti-HER2 therapy and established a stable cell line named CK-MB-1. This cell line retained the main characteristics of the primary tumor, including HER2 positivity and estrogen receptor negativity. Through fluorescence in situ hybridization (FISH), the amplification of the HER2 gene in CK-MB-1 cells was confirmed. Additionally, the expression of phosphatase and tensin homolog (PTEN) protein in CK-MB-1 cells was normal with no gene mutations, and no common phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutations were detected. Compared to two other HER2-positive trastuzumab-resistant cell lines, CK-MB-1 cells exhibited stronger resistance to trastuzumab, chemotherapeutic drugs, and small molecule drugs.

In in vivo experiments, researchers used CK-MB-1 cells to establish xenograft tumor models in zebrafish and immunodeficient mice (NOD SCID mice). These models further confirmed the trastuzumab resistance of CK-MB-1 cells. Therefore, the CK-MB-1 cell line and its related models can serve as effective tools for studying new therapies targeting HER2-positive, trastuzumab-resistant, and PIK3CA/PTEN wild-type breast cancer. This is clinically significant for understanding this larger proportion of trastuzumab-resistant breast cancer patient population.